英格兰2000-2019年出生儿童接种首剂与第二剂MMR疫苗后特发性血小板减少性紫癜风险
研究评估英格兰2000-2019年出生儿童接种首剂和第二剂MMR疫苗后特发性血小板减少性紫癜(ITP)风险。采用自控病例系列方法分析接种后6周内住院ITP相对发生率,发现首剂后风险升高(相对发生率2.38,95%CI 2.12-2.67),第二剂后无风险升高证据,首剂后发生ITP的儿童接种第二剂亦安全。
要点
- 首剂MMR后6周内ITP风险升高,相对发生率2.38(95%CI 2.12-2.67)。
- 第二剂MMR后未见ITP风险升高,相对发生率0.96(95%CI 0.81-1.13)。
- 首剂后发生ITP的儿童接种第二剂未见风险升高,可安全接种。
核心结论
- 首剂MMR疫苗接种后6周内ITP风险升高,第二剂后无风险升高证据。
- 首剂后发生ITP的儿童接种第二剂MMR未增加ITP风险,可安全接种。
研究设计与样本
- 研究纳入英格兰2000-2019年出生儿童,链接住院ITP病例与MMR疫苗接种记录。
- 采用自控病例系列方法评估接种后6周内ITP相对发生率。
主要发现
- 首剂MMR后ITP相对发生率为2.38(95%CI 2.12-2.67),归因风险为每42,900剂1例。
- 第二剂MMR后ITP相对发生率为0.96(95%CI 0.81-1.13),无风险升高证据。
- 336名首剂后发生ITP的儿童接种第二剂后6周内未见ITP风险升高。
临床怎么用
- 首剂MMR接种后应关注ITP风险,但归因风险较低。
- 首剂后发生ITP的儿童可按程序接种第二剂MMR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the risk of Idiopathic thrombocytopenic purpura (ITP) after Measles Mumps Rubella vaccine (MMR) doses 1 and 2 in children in England born from 2000 to 2019. After linking hospitalised ITP episodes to MMR vaccine records, we used the self-control case-series method to assess the relative incidence in the 6-week period post vaccination. We also assessed the risk of ITP after dose 2 in those who had ITP after dose 1. We found an increased risk of ITP after dose 1 (relative incidence 2.38 (95% CI: 2.12-2.67)) with an attributable risk of 1 in 42,900 doses. We found no evidence of an increased risk after dose 2 (relative incidence 0.96 (95% CI: 0.81-1.13)). Furthermore, we found that the 336 children with ITP after dose 1 who had MMR dose 2 had no increased risk in the 6-weeks after this dose and that it is therefore safe to vaccinate these children.
引用
- Andrews N, Stowe J, Hani E, et al. The risk of idiopathic thrombocytopenic purpura after first and second measles, mumps, rubella (MMR) vaccine doses in children born in England 2000-2019. Vaccine. 2026. PMID: 42771940. doi:10.1016/j.vaccine.2026.129168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。